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VALIDATION OF A SOLUBLE INTERLEUKIN-2 RECEPTOR ASSAY FOR THE
DIAGNOSTIC OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN INDIAN
CHILDREN
Veronique Dinand, Sakshi Sharma, Nita Radhakrishnan, Anupam
Sachdeva. Pediatric Hematology Oncology and BMT Unit, Sir Ganga Ram
Hospital, New Delhi, India
Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a cellular
immune dysregulation caused by underlying genetic defects (Primary) or
triggered by infection, malignancies or rheumatological conditions.
Although raised soluble interleukin-2 receptor (sIL2-R, CD25) has been
suggested as a biomarker, it is not routinely measured in India. The
objective of the present study was to establish an assay and validate the
cut-off value of sIL2-R for the diagnosis of HLH in Indian children.
Methods: Children with persistent fever, organomegaly, cytopenias
with biochemical markers of HLH (fulﬁlling the criteria) were labeled
as cases. Peripheral blood serum of cases and healthy was cry-
opreserved. A double-sandwich enzyme immune assay was used to
measure sIL2-R in a ﬁrst batch of cases and controls. Standards and
samples were run in duplicates. The optimum cutoff value was deter-
mined using ROC curve, and validated in a second batch of suspected
HLH cases and controls.
Results: 74 children were enrolled (28 suspected HLH, 46 controls), with
similar age/ sex distribution. The optimal sIL2R cutoff of 12ng/ml was
found to be equivalent to 2400U/ml in the standardization batch (16 cases/
22 controls). This cut-off in the validation batch (12 suspected cases and 24
controls) conﬁrmed HLH in 11 cases, while it excluded HLH in 1 possible
case. sIL2-R was higher in familial (n¼8; median 4500U/ml [IQR:
3,305e4,183]) than HLH secondary to infective trigger, malignancy or
SOJIA (n¼19; median 4500U/ml [IQR: 3,305e4,183] vs. 2,810U/ml
[1,655e3,720], p<0.001). On analyzing the prognostic signiﬁcance of sIL2-
R, sIL2- R3200U/ml was signiﬁcantly associated with mortality (85.7% vs.
20.0% in patients with sIL2- R<3200, p¼0.003).
Conclusion: A simple sIL2-R assay was successfully established. sIL2-R is
higher in primary HLH and can aid in diagnosis and predict mortality
especially when molecular diagnosis is delayed or not available. Normal




FOLATE/VITAMIN B12 DEFICIENCY IN CHILDREN WITH ACUTE
LYMPHOBLASTIC LEUKEMIA: BREAKING THE MYTH
Sanjeev Khera, Amita Trehan, Savita Attri, Richa Jain, Deepak
Bansal. PGIMER, Chandigarh, India
Background: VitaminB12& Folicacid (FA) supplementation inpatientswith
a malignancy are considered counter-productive by making the cell stroma
conducive to the proliferation of the malignant clone. Patients in lower
middle income countries (LMIC's) have greater incidence of malnutrition
with vitamin deﬁciencies. The need for refraining from supplementation of
FA to patients with a malignancy in LMIC's has been questioned.
Aim: To evaluate the incidence of vitamin B12/FA deﬁciency in children on
therapy for Acute Lymphoblastic Leukemia (ALL).
Materials & Methods: Children with ALL on therapy were randomly
evaluated for serum B12 and folate levels. Serum B12 < 211pg/ml and
serum Folate < 2 ng/ml were taken as deﬁcient levels. Deﬁciency status
was correlated to under-nutrition. Weight for age < -2z score was taken as
under-nutrition (WHO).
Results: 85 children with mean age 6.8 yrs (6.03-7.73), including 50 on
maintenance and 35 on induction/consolidation chemotherapy were
evaluated.50 age and sex matched controls were also evaluated.
Induction/ Consolidation: 7/35 children (20%) were undernourished.
Mean B12 levels were 330.4pg/ml (227.76-345.84), with 11 (32%) beingB12 deﬁcient. 2/11 patients were undernourished. Only1 child had folate
deﬁciency, the mean levels being 8.55ng/ml (5.85-11.13).
Maintenance Therapy: 14 children (28%) were malnourished. Mean B12
levels were 500.56pg/ml (419.74-581.38). B12 deﬁciency was seen in 5
(10%) patients, with 3/5 being under-nourished. Mean Folate levels were
6.61ng/ml (5.56-7.66), deﬁciency being seen in 4 (8%) patients 3 of whom
were under-nourished.
There was no difference of B12 & Folate levels when sex, T/B cell ALL,
standard risk Vs high/intermediate risk ALL were compared. Undernour-
ished children had signiﬁcantly low levels of Folate (4.59 Vs 7.4; p¼0.0139).
This difference was not observed with B12 levels.
50 age/sex matched children taken as controls did not have either
deﬁciency.
Conclusion: Under-nutrition in India is 45.9% as per National Family
Health Survey (NFHS)-3 with reported prevalence of B12& FA deﬁciency in
the general population to be 7-33% and 20-33%; with a even higher
prevalence in the undernourished. 25% of our cohort had under-nutrition.
We had 5.8% with Folate & 20% childrenwith B12 deﬁciency. Patients with
co existing malnutrition had greater B12/FA deﬁciency. Higher B12 deﬁ-
ciency in induction/consolidation which may be due to higher demands or
drug interactions needs further evaluation. A larger cohort would help
conclude and nullify the hypothesis of FA supplementation to cancer pa-
tient in LMIC's. Under-nutrition in LMIC's remains the main issue to be
tackled.
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INVESTIGATING HEPATITIS B IMMUNITY IN CHILDREN WITH ACUTE
LYMPHOBLASTIC LEUKEMIA PRESENTING AT A TERTIARY CANCER
CARE CENTRE
V.R. Prasanth, T. Priyakumary, Parukuttyamma Kusumakumary. Division of
Pediatric Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala,
India
Background: Hepatitis B is a dreaded infectious disease and one of the
major global public health problems and is the tenth leading cause of
death. The global disease burden is staggering with about two billion
people acutely infected and nearly 350 million chronically infected with
hepatitis B virus (HBV). In India, the prevalence of hepatitis B surface an-
tigen (HBsAg) among the general population ranges from 2% to 8%, placing
India in an intermediate HBV endemicity zone. Our country has over 50
million cases making it the second largest global pool of chronic HBV in-
fections. Waning of vaccine induced immunity leaves people at risk of
acquiring hepatitis B infection in settings where the prevalence of infec-
tion is high .Vaccine- induced seroprotection (AntiHBs) is a useful surro-
gate of vaccine efﬁcacy.
Objective: To assess immunity to Hepatitis B virus at initial presentation in
children with newly diagnosed ALL treated in the Paediatric Oncology
Division, Regional Cancer Centre, Thiruvanathapuram, Kerala.
Methods: Children (0-14 years) with newly diagnosed ALL treated be-
tween January 2016 to August 2016 were evaluated. Data regarding pri-
mary HB immunization were collected from the immunization
card.AntiHBsAg titers were done at presentation using Enzyme Linked
Fluoroscent Assay method using VIDAS (Bio-Merieux).Patients were clas-
siﬁed as immune (antibody levels to hepatitis B surface antigen (antiHBs)
>100mIU/ml), lowimmune (antiHBs10-100mIU/ml) and not immune
(antiHBs<10 mIU/ml).
Results: Of the 109 children included (median age 5.6 years, M:F-
1.5:1),75(68.8%) children had protective antiHBstitres (>10IU/L),34(31.2%)
children had no immunity to hepatitis B.Of the 75 childrenwith protective
antiHBstitres 37 children (49.33%) had low immune antiHBstitres (10-
100mIU/ml) and 38 children (50.66%) had immune antiHBstitres> 100
mIu/ml.Nopatients had active hepatitis B infection (hepatitis B surface
antigenpositive) at presentation.
Discussion: Acute Lymphoblastic Leukemia (ALL) is the most common
malignant disease in children.The more intensive treatment and risk
stratiﬁcation adopted over the last decade have resulted in an improve-
ment in the survival rate, which, in many cases, reaches 90%.Both the
illness and treatment affect the immune system. Immune competence
